ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study)

Farid Kheloufi , Isabelle Poizot-Martin (1) , Rodolphe Garraffo (2) , Aude Tavenard (3) , Sylvie Quaranta , Alain Renault (3) , Thibault Lavrut , Marc Bourlière , Philippe Halfon (4) , Lionel Piroth , Eric Bellissant (3) , Bruno Lacarelle , Jean-Michel Molina (5) , Caroline Solas

1 SESSTIM - U912 INSERM - Aix Marseille Univ - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
2 Service de pharmacologie
3 CIC - Centre d'Investigation Clinique [Rennes]
4 Hôpital Européen [Fondation Ambroise Paré - Marseille]
5 Service des Maladies Infectieuses et Tropicales [CHU Saint Louis]

Domains: Life Sciences [q-bio]

Farid Kheloufi, Isabelle Poizot-Martin, Rodolphe Garraffo, Aude Tavenard, Sylvie Quaranta, et al.. ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). Antiviral Therapy, 2017, 22 (6), pp.461-469. ⟨10.3851/IMP3074⟩. ⟨hal-01671461⟩